ReproCELL Incorporated (4978.T)
JPY 151.0
(4.14%)
JPY 151.0
(4.14%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -409.29 Million JPY | -14.9% |
| 2022 | -356.22 Million JPY | 44.95% |
| 2021 | -647.12 Million JPY | 38.25% |
| 2020 | -1.04 Billion JPY | -15.3% |
| 2019 | -908.93 Million JPY | -16.36% |
| 2018 | -781.11 Million JPY | 23.85% |
| 2017 | -1.02 Billion JPY | -8.63% |
| 2016 | -944.3 Million JPY | 7.82% |
| 2015 | -1.02 Billion JPY | -38.31% |
| 2014 | -740.65 Million JPY | -694.02% |
| 2013 | -93.27 Million JPY | -106.64% |
| 2012 | -45.14 Million JPY | 53.58% |
| 2011 | -97.25 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -115 Million JPY | 4.14% |
| 2023 Q1 | -124.07 Million JPY | 16.71% |
| 2023 FY | -409.29 Million JPY | -14.9% |
| 2023 Q4 | -119.96 Million JPY | -151.18% |
| 2023 Q3 | -47.76 Million JPY | 59.35% |
| 2023 Q2 | -117.49 Million JPY | 5.31% |
| 2022 Q1 | -86.68 Million JPY | 26.42% |
| 2022 FY | -356.22 Million JPY | 44.95% |
| 2022 Q4 | -148.96 Million JPY | -27.19% |
| 2022 Q3 | -117.12 Million JPY | -3286.01% |
| 2022 Q2 | -3.45 Million JPY | 96.01% |
| 2021 FY | -647.12 Million JPY | 38.25% |
| 2021 Q4 | -117.79 Million JPY | 30.66% |
| 2021 Q3 | -169.87 Million JPY | -105.19% |
| 2021 Q2 | -82.78 Million JPY | 70.08% |
| 2021 Q1 | -276.66 Million JPY | 2.39% |
| 2020 Q2 | -212.59 Million JPY | 26.58% |
| 2020 FY | -1.04 Billion JPY | -15.3% |
| 2020 Q1 | -289.55 Million JPY | -22.0% |
| 2020 Q3 | -262.45 Million JPY | -23.45% |
| 2020 Q4 | -283.45 Million JPY | -8.0% |
| 2019 Q3 | -239.32 Million JPY | -15.98% |
| 2019 FY | -908.93 Million JPY | -16.36% |
| 2019 Q4 | -237.33 Million JPY | 0.83% |
| 2019 Q1 | -225.94 Million JPY | -16.84% |
| 2019 Q2 | -206.34 Million JPY | 8.67% |
| 2018 FY | -781.11 Million JPY | 23.85% |
| 2018 Q4 | -193.38 Million JPY | -5.93% |
| 2018 Q3 | -182.56 Million JPY | 0.77% |
| 2018 Q2 | -183.98 Million JPY | 16.82% |
| 2018 Q1 | -221.19 Million JPY | 12.7% |
| 2017 Q1 | -274.63 Million JPY | 14.24% |
| 2017 Q4 | -253.38 Million JPY | -7.44% |
| 2017 Q3 | -235.83 Million JPY | 9.96% |
| 2017 Q2 | -261.93 Million JPY | 4.62% |
| 2017 FY | -1.02 Billion JPY | -8.63% |
| 2016 Q1 | -245.68 Million JPY | 21.75% |
| 2016 FY | -944.3 Million JPY | 7.82% |
| 2016 Q4 | -320.24 Million JPY | -106.77% |
| 2016 Q3 | -154.87 Million JPY | 30.7% |
| 2016 Q2 | -223.49 Million JPY | 9.03% |
| 2015 Q3 | -285.4 Million JPY | -36.65% |
| 2015 Q2 | -208.86 Million JPY | 3.4% |
| 2015 Q1 | -216.2 Million JPY | 34.22% |
| 2015 Q4 | -313.96 Million JPY | -10.01% |
| 2015 FY | -1.02 Billion JPY | -38.31% |
| 2014 Q1 | -68.87 Million JPY | -192.86% |
| 2014 Q4 | -328.65 Million JPY | -49.43% |
| 2014 Q3 | -219.93 Million JPY | -78.53% |
| 2014 Q2 | -123.19 Million JPY | -78.87% |
| 2014 FY | -740.65 Million JPY | -694.02% |
| 2013 FY | -93.27 Million JPY | -106.64% |
| 2013 Q3 | -26.12 Million JPY | 1.52% |
| 2013 Q1 | -17.1 Million JPY | 0.0% |
| 2013 Q2 | -26.53 Million JPY | -55.15% |
| 2013 Q4 | -23.51 Million JPY | 10.0% |
| 2012 FY | -45.14 Million JPY | 53.58% |
| 2011 FY | -97.25 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 596.82 Million JPY | 168.579% |
| PRISM BioLab Co.,LTD | -496.86 Million JPY | 17.625% |
| GNI Group Ltd. | 13.1 Billion JPY | 103.122% |
| Linical Co., Ltd. | 725.72 Million JPY | 156.398% |
| Trans Genic Inc. | 89.43 Million JPY | 557.638% |
| MEDINET Co., Ltd. | -1.42 Billion JPY | 71.297% |
| Soiken Holdings Inc. | -610 Million JPY | 32.904% |
| Cytori Cell Research Institute, Inc. | -772.74 Million JPY | 47.034% |
| AnGes, Inc. | -11.96 Billion JPY | 96.58% |
| OncoTherapy Science, Inc. | -1.12 Billion JPY | 63.482% |
| Nxera Pharma Co., Ltd. | -9.52 Billion JPY | 95.703% |
| Immuno-Biological Laboratories Co., Ltd. | 104.29 Million JPY | 492.423% |
| NanoCarrier Co., Ltd. | -864.41 Million JPY | 52.651% |
| Carna Biosciences, Inc. | -1.11 Billion JPY | 63.357% |
| CanBas Co., Ltd. | -1.26 Billion JPY | 67.568% |
| D. Western Therapeutics Institute, Inc. | -798.55 Million JPY | 48.746% |
| RaQualia Pharma Inc. | -337.36 Million JPY | -21.321% |
| Chiome Bioscience Inc. | -1.2 Billion JPY | 66.039% |
| Kidswell Bio Corporation | -1.33 Billion JPY | 69.355% |
| PeptiDream Inc. | 6.77 Billion JPY | 106.043% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 78.793% |
| Ribomic Inc. | -1.11 Billion JPY | 63.331% |
| SanBio Company Limited | -4.53 Billion JPY | 90.983% |
| Healios K.K. | -3.37 Billion JPY | 87.887% |
| BrightPath Biotherapeutics Co., Ltd. | -1.15 Billion JPY | 64.566% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 70.629% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 70.827% |
| StemRIM | -2.07 Billion JPY | 80.285% |
| CellSource Co., Ltd. | 1.22 Billion JPY | 133.507% |
| FunPep Company Limited | -994 Million JPY | 58.824% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 53.948% |
| Stella Pharma Corporation | -760.3 Million JPY | 46.167% |
| TMS Co., Ltd. | -943.25 Million JPY | 56.608% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 47.215% |
| Cuorips Inc. | -588.48 Million JPY | 30.45% |
| K Pharma,Inc. | 366.05 Million JPY | 211.811% |
| Takara Bio Inc. | 3 Billion JPY | 113.629% |
| PhoenixBio Co., Ltd. | 11.06 Million JPY | 3799.657% |
| StemCell Institute Inc. | 413.75 Million JPY | 198.921% |
| Japan Tissue Engineering Co., Ltd. | 144.5 Million JPY | 383.234% |
| CellSeed Inc. | -697.77 Million JPY | 41.343% |